Biologic treatment of pediatric inflammatory bowel disease: A decade of JPGN contributions

Melvin B. Heyman, Raanan Shamir

Research output: Book/ReportBookpeer-review

Abstract

Drug development in children and adolescents occasionally is hindered by a hesitance to expose young patients to experimental and untested therapies, such as the application of biologic agents for pediatric patients with inflammatory bowel disease (IBD). This collection of articles from JPGN represent seminal work on the application, safety, and efficacy of the 2 leading anti-TNF agents, infliximab and adalimumab, to assist readers in considering treatment options and further advances in the care of pediatric patients with chronic IBD.

Original languageEnglish
PublisherWolters Kluwer Health Adis (ESP)
Number of pages379
ISBN (Electronic)9781469887142
ISBN (Print)9781469887166
StatePublished - 24 Apr 2014

Fingerprint

Dive into the research topics of 'Biologic treatment of pediatric inflammatory bowel disease: A decade of JPGN contributions'. Together they form a unique fingerprint.

Cite this